Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486

Kidney International

Volumn 82, Issue 4, 2012, Pages 401-411

  Xu, Jing ^a,b   Li, Rongshan ^c   Workeneh, Biruh ^b   Dong, Yanlan ^b   Wang, Xiaonan ^d   Hu, Zhaoyong ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SHANXI MEDICAL UNIVERSITY   (China)

^d EMORY UNIVERSITY   (United States)

Author keywords

chronic kidney disease (CKD); FoxO1; microRNA; miR 486; muscle wasting

Indexed keywords

ATROGIN 1; MICRORNA; MICRORNA 486; MUSCLE RING FINGER 1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR FKHR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA INTERFERENCE;

EID: 84864571647     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.84     Document Type: Article

References (43)

1. Du J, Wang X, Miereles C et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113: 115-123.
2. Hu Z, Lee IH, Wang X et al. PTEN expression contributes to the regulation of muscle protein degradation in diabetes. Diabetes 2004; 56: 2449-2456.
3. Lee SW, Dai G, Hu Z et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004; 15: 1537-1545.
4. Wang XH, Zhang L, Mitch WE et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem 2010; 285: 21249-21257.
5. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitinproteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17: 1807-1819.
6. Lecker SH, Jagoe RT, Gilbert A et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18: 39-51.
7. Bodine SC, Latres E, Baumhueter S et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-1708.
8. Gomes MD, Lecker SH, Jagoe RT et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98: 14440-14445.
9. Stitt TN, Drujan D, Clarke BA et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395-403.
10. Sandri M, Sandri C, Gilbert A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
11. Senf SM, Dodd SL, Judge AR. FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am J Physiol Cell Physiol 2010; 298: C38-C45.
12. Smith IJ, Alamdari N, O'Neal P et al. Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism. Int J Biochem Cell Biol 2010; 42: 701-711.
13. Moylan JS, Smith JD, Chambers MA et al. TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am J Physiol Cell Physiol 2008; 295: C986-C993.
14. Farh KK, Grimson A, Jan C et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821.
15. Lagos-Quintana M, Rauhut R, Yalcin A et al. Identification of tissuespecific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
16. Eisenberg I, Eran A, Nishino I et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA 2007; 104: 17016-17021.
17. van RE, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369-2376.
18. Eisenberg I, Alexander MS, Kunkel LM. miRNAS in normal and diseased skeletal muscle. J Cell Mol Med 2009; 13: 2-11.
19. Chen JF, Tao Y, Li J et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol 2010; 190: 867-879.
20. Wang XH, Hu Z, Klein JD et al. Decreased miR-29 suppresses myogenesis in CKD. J Am Soc Nephrol 2011; 22: 2068-2076.
21. Small EM, O'Rourke JR, Moresi V et al. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci USA 2010; 107: 4218-4223.
22. Hu Z, Wang H, Lee IH et al. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest 2009; 119: 3059-3069.
23. Hwee DT, Gomes AV, Bodine SC. Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment. Am J Physiol Endocrinol Metab 2011; 301: E967-E977.
24. Waddell DS, Baehr LM, van den Brandt J et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 2008; 295: E785-E797.
25. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121: 1022-1032.
26. Reed SA, Sandesara PB, Senf SM et al. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J 2012; 26: 987-1000.
27. Bailey JL, Zheng B, Hu Z et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006; 17: 1388-1394.
28. Zhang L, Wang XH, Wang H et al. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 2010; 21: 419-427.
29. Hu Z, Wang H, Lee IH et al. PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. Diabetes 2010; 59: 1312-1320.
30. May RC, Kelly RA, Mitch WE. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis. J Clin Invest 1987; 79: 1099-1103.
31. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007; 292: C188-C199.
32. Plant PJ, Bain JR, Correa JE et al. Absence of caspase-3 protects against denervation-induced skeletal muscle atrophy. J Appl Physiol 2009; 107: 224-234.
33. Verzola D, Procopio V, Sofia A et al. Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease. Kidney Int 2011; 79: 773-782.
34. Acharyya S, Ladner KJ, Nelsen LL et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370-378.
35. Zhang L, Rajan V, Lin E et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25: 1653-1663.
36. Kitamura T, Kitamura YI, Funahashi Y et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest 2007; 117: 2477-2485.
37. Alexander MS, Casar JC, Motohashi N et al. Regulation of DMD pathology by an ankyrin-encoded miRNA. Skelet Muscle 2011; 1: 27.
38. Lai KM, Gonzalez M, Poueymirou WT et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004; 24: 9295-9304.
39. Wang XH, Du J, Klein JD et al. Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int 2009; 76: 751-759.
40. Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 2011; 12: 19-31.
41. Aouadi M, Tesz GJ, Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009; 458: 1180-1184.
42. Wang H, Liu D, Cao P et al. Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes 2010; 59: 1879-1889.
43. Runge SR, Hu Z, Runge MS. In situ hybridization. Methods Mol Med 2001; 51: 223-233.